Literature DB >> 7553998

Substitution of mivacurium for succinylcholine for ECT in elderly patients.

K Janis1, J Hess, J A Fabian, M Gillis.   

Abstract

Three cases are reported where pre-existing medical conditions (severe osteoporosis, amyotrophic lateral sclerosis, cardiac arrhythmias) made the administration of succinylcholine during ECT potentially dangerous. Therefore, mivacurium was substituted as the muscle relaxant necessary for safe therapy. Full reversal of the non-depolarizing muscle relaxant was assured by post-reversal use of the peripheral nerve stimulator with full recovery of train-of-four response.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7553998     DOI: 10.1007/BF03011879

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   5.063


  5 in total

1.  The clinical neuromuscular pharmacology of mivacurium chloride (BW B1090U). A short-acting nondepolarizing ester neuromuscular blocking drug.

Authors:  J J Savarese; H H Ali; S J Basta; P B Embree; R P Scott; N Sunder; J N Weakly; W B Wastila; H A el-Sayad
Journal:  Anesthesiology       Date:  1988-05       Impact factor: 7.892

Review 2.  Electroconvulsive therapy and anesthetic considerations.

Authors:  G Y Gaines; D I Rees
Journal:  Anesth Analg       Date:  1986-12       Impact factor: 5.108

3.  Mivacurium in electroconvulsive therapy.

Authors:  R M Burnstein; N Denny
Journal:  Anaesthesia       Date:  1993-12       Impact factor: 6.955

4.  Use of muscle relaxants for electroconvulsive therapy: how much is enough?

Authors:  B Fredman; I Smith; J d'Etienne; P F White
Journal:  Anesth Analg       Date:  1994-01       Impact factor: 5.108

5.  Is mivacurium chloride effective in electroconvulsive therapy? A report of four cases, including a patient with myasthenia gravis.

Authors:  M C Gitlin; J S Jahr; M A Margolis; J McCain
Journal:  Anesth Analg       Date:  1993-08       Impact factor: 5.108

  5 in total
  4 in total

1.  Use of rocuronium-sugammadex, an alternative to succinylcholine, as a muscle relaxant during electroconvulsive therapy.

Authors:  Hiroko Hoshi; Yuji Kadoi; Jiro Kamiyama; Akiko Nishida; Hiroyuki Saito; Masaki Taguchi; Shigeru Saito
Journal:  J Anesth       Date:  2011-02-04       Impact factor: 2.078

2.  Divided doses of methohexitone improves ECT outcome.

Authors:  S Gurmarnik; R Young; E Alesker
Journal:  Can J Anaesth       Date:  1996-05       Impact factor: 5.063

3.  Comparison of recovery times from rocuronium-induced muscle relaxation after reversal with three different doses of sugammadex and succinylcholine during electroconvulsive therapy.

Authors:  Yuji Kadoi; Hiroko Hoshi; Akiko Nishida; Shigeru Saito
Journal:  J Anesth       Date:  2011-09-24       Impact factor: 2.078

4.  Ect in neurological counditions.

Authors:  K Girish; B N Gangadhar; N Janakiramaiah
Journal:  Indian J Psychiatry       Date:  2002-07       Impact factor: 1.759

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.